STOCKHOLM, August 25, 2014 – Elekta today announced its intention to acquire
RTA, a leading distributor from Poland specializing in cutting-edge radiation
therapy technologies. The acquisition will significantly strengthen Elekta’s
position in the Polish cancer care market.
With the incidence of cancer in Poland expected to increase by almost 19 percent
between 2012 and 2025*, the need for treatment equipment will escalate
accordingly. Today Poland has just over 100 linear accelerators (linacs) used to
deliver radiation therapy to treat cancer, but according to E Rosenblatt MD, et
al**, the optimal number of linacs for country is almost 200.

“The acquisition of RTA would optimally position Elekta to capture the
opportunities for the growth of radiation therapy in Poland,” says Niklas
Savander, President and CEO of Elekta. “Developing the multi-year relationship
we have with RTA into the establishment of an Elekta office, is an important
step on our path to higher growth.”

Acquiring RTA is expected to add approximately 0.3 percent to Elekta’s revenues
on an annual basis. Once approved, the transaction is expected to be EPS
accretive on an annual basis. Once the agreement has been signed and approved, a
three-year earn out component between seller and Elekta is expected.

Closing will take place in January 2015. RTA will then change its name to Elekta
and will be a wholly-owned subsidiary.

* GLOBOCAN
2012 (http://globocan.iarc.fr/old/burden.asp?selection_pop=156616&Text
-p=Poland&selection_cancer=290&Text-c=All+cancers+excl.+non
-melanoma+skin+cancer&pYear=13&type=0&window=1&submit=%C2%A0Execute%C2%A0)
** Radiotherapy capacity in European countries: an analysis of the Directory of
Radiotherapy Centres (DIRAC) database, Lancet Oncol 2006; 7:
584–95 (http://dx.doi.org/doi:10.1016/S1470-2045(12)70556-9)

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on August 25, 2014.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.